Key result
Japan reports ~270 destination therapy iVAD implants alongside regenerative and allocation advances in HF surgery.
Why the study?
With an aging population, the number of heart failure patients continues to increase, and cases of drug-refractory severe heart failure require tailored multidisciplinary surgical strategies including tMCS, iVAD, heart transplantation, and regenerative medicine.
This narrative review summarizes 2025 advances in heart failure surgery, highlighting the expansion of destination therapy with implantable VADs, Impella 5.5 perioperative strategies, organ allocation updates, DCD and xenotransplantation, and conditional approval of human iPSC-derived cardiomyocyte sheets in Japan.
Answers are grounded in this paper and cite their sources.
May inform Japanese HF surgical strategies; leaves open need for outcome data and broader validation.
circulatory support: tMCS)
No takes yet. Share an insight, caveat, or question.
Fujiwara et al. (2026) conducted a review in Severe heart failure. Surgical treatments for severe heart failure (tMCS, iVAD, heart transplantation, and iPS cell-derived cardiomyocyte sheets) was evaluated. Advances in 2025 heart failure surgery included 272 destination therapy iVAD cases in Japan, conditional approval of iPS cell sheets, and new Status 1A transplant allocation.
Synapse has enriched 10 related papers. Consider them for comparative context: